ID | 1076 |
Name of the vaccine | Tenivac |
Microbe | Bacteria |
Disease name | Tetanus (Lock Jaw) |
Name of bacteria | Clostridium tetani |
Type of vaccine | Inactivated |
Nucleic acid content | DNA |
Age | 7 years and older |
Description of the vaccine | Tetanus and diphtheria toxoids adsorbed (Td vaccine). |
Name of the manufacturer | Sanofi Pasteur Limited |
Name of the manufacturing country | Canada |
Year of manufacture | 2003 |
Clinical Phase status | Approved |
Bacterial strain | An obligate anaerobic bacillus, which is gram positive. |
Efficacy | NA |
Vaccine formulation | Suspension for injection |
Dosage | Primary Immunization - Three 0.5 mL doses.
Routine Booster - Recommended in children 11-12 years of age and every 10 years. |
Mechanism of action | Serum tetanus antitoxin level of greater than or equal to 0.1 IU/mL is protective. |
Route of administration | Intramuscular |
Indications | Active immunization for the prevention of tetanus and diphtheria. |
Export | Distributed by Sanofi Pasteur Inc, USA |
Approval | US FDA |
Adjuvant | Aluminium phosphate |
Repurposing | For diphtheria also. |
Side effects of vaccine | Pain, headache, injection site redness, injection site swelling, malaise, muscle weakness and pain in joints. |
Post vaccination | NA |
Dose type | Combination doses |
Interspecies transfer | NA |
PubMed identifier | NA |
Clinical trial number | NA |
Reference | https://www.fda.gov/media/76610/download |
Other name | NA |
Additional Links | NA
|